Chronic kidney disease (CKD) represents one of the major non-communicable diseases affecting populations worldwide. It is characterized by a gradual decline in renal function resulting from persistent structural or functional abnormalities of the kidneys, eventually leading to impaired filtration capacity and multiple systemic complications. Persistent renal dysfunction is accompanied by immune dysregulation and chronic inflammation, leading to altered production of several cytokines and inflammatory mediators., Increasing evidence indicates that chronic inflammation plays a central role in CKD progression, while circulating visfatin has emerged as an inflammatory adipokine closely linked to metabolic and immune alterations in these patients, cellular stress responses and metabolism. This investigation was designed to quantify serum concentrations of visfatin, interleukin-17A, beta2-microglobulin, and interleukin-22 in individuals with chronic kidney disease and to compare these biomarkers with those measured in healthy participants. A case-control study was performed between January and June 2025 involving 90 participants, including 60 clinically diagnosed CKD patients and 30 apparently healthy controls., serum samples were collected to measure the level of visfatin, interleukin 17A, beta2-microglobulin and interleukin 22 by ELIZA technique, which is based on the Sandwich ELIZA principle. The results of the study showed a significant increase in the level of visfatin in patients with CKD (7.25 ± 0.6 pg/ml) compared to controls (3.6 ± 0.3 pg/ml). The results of the study also showed a highly significant increase in the level of interleukin 17A, beta 2 microglobulin and interleukin 22 in patients with CKD (24. 39 ± 7.2 pg/ml, 6.86 ± 1.7 ng/ml, and 185.7 ± 20.5 pg/ml) respectively, compared with controls (3.22 ± 0.77 pg/ml, 2.53 ± 0.74 ng/ml, and 89.4 ± 15.3 pg/ml) respectively. These findings indicate that elevated serum levels of visfatin, interleukin-17A, beta2-microglobulin, and interleukin-22 are closely associated with chronic kidney disease and may serve as useful biomarkers reflecting immune activation and inflammatory status in affected patients.